Vivani Medical Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion Visual Cortical Prosthesis System
Portfolio Pulse from Benzinga Newsdesk
Vivani Medical, Inc. (NASDAQ:VANI) announced that its subsidiary Cortigent, Inc. has completed the fifth year of its Early Feasibility Study (EFS) of profoundly blind patients implanted with the Orion® Visual Cortical Prosthesis System. The study, funded by the National Institutes of Health, reported no device malfunctions and a single serious adverse event which resolved quickly and resulted in no permanent harm.
July 11, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivani Medical's successful completion of the 5-year study for its Orion Visual Cortical Prosthesis System indicates positive progress in its product development, which could potentially boost investor confidence.
The successful completion of the 5-year study by Vivani Medical's subsidiary Cortigent indicates that the Orion Visual Cortical Prosthesis System is functioning as expected, with no device malfunctions reported. This positive progress in product development could potentially boost investor confidence in Vivani Medical, leading to a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100